AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03327610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSV25
Description: Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 25% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
Study NCT01391481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perfluorocarbon
Description: Vaporized PFC Inhalation 100ml/8h for 5 days
Study NCT01391481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Water for Injection
Description: Inhalation of Sterile Water for Injection, 100ml/8h for 5 days
Study NCT01486654 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation - Cathodal stimulation
Description: Cathodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
Study NCT01486654 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation - Anodal stimulation
Description: Anodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
Study NCT01486654 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation - Sham stimulation
Description: Sham stimulation provided together with 90 minutes of speech language therapy, 5 days a week, for 6 weeks.
Study NCT04173325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]
Description: PD-1 inhibitor approved by the US FDA for treatment of patients with lung cancer.
Study NCT04173325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Injection [Camptosar]
Description: Chemotherapy drug currently FDA approved for treatment of multiple tumors, including small cell lung cancer.
Study NCT00687830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol afternoon
Description: Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Evening prep, between 5PM and 9PM
Study NCT00687830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol morning
Description: Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Morning prep, between 6AM and 10AM
Study NCT00698711 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC-2-KLH
Description: The MUC-2-KLH conjugate will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4 week break and then a fourth vaccination during week 7, and 3 months later during week 19. Booster vaccinations may be given at or after week 50 and 100, and every 6 months thereafter to select patients who show no evidence of radiographic disease progression.~After 5 patients have been enrolled and completed two vaccinations without Grade II or greater toxicity, we will proceed to the next higher dose level. No dose escalations will be performed in the same patient.
Study NCT03908437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: A mobile team will be led by a nurse practitioner (able to prescribe buprenorphine/naloxone in PA) and include a peer recovery specialist (PRS), and a case manager. The team will rapidly confirm opioid use disorder and risk of overdose, complete informed consent, and begin induction procedures for a transitional (one month) course of buprenorphine/naloxone treatment. During this time, the dedicated case manager and PRS will work with the participants to help them become engaged in existing medication assisted treatment programs
Study NCT03908437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine/naloxone
Description: A mobile team will be led by a nurse practitioner (able to prescribe buprenorphine/naloxone in PA) and include a peer recovery specialist (PRS), and a case manager. The team will rapidly confirm opioid use disorder and risk of overdose, complete informed consent, and begin induction procedures for a transitional (one month) course of buprenorphine/naloxone treatment. During this time, the dedicated case manager and PRS will work with the participants to help them become engaged in existing medication assisted treatment programs
Study NCT03391596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based ACT intervention
Description: The Internet-based ACT intervention is a 12-week program based on the processes of Acceptance and Commitment Therapy.
Study NCT03391596 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized rehabilitation
Description: Standardized institutional rehabilitation in a rehabilitation center
Study NCT02421588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin (PM01183)
Study NCT02421588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Study NCT02421588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Study NCT04292743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eryaspase
Description: intravenous administration of Eryaspase, starting dose 75 units/kg, dose escalation to 100 units/kg, dose reduction 50 units/kg and 25 units/kg
Study NCT04292743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: intravenous administration of FOLFIRINOX
Study NCT03391596 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Support by voluntary caregiver associations
Description: Support given by voluntary caregiver associations
Study NCT02563938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK001
Description: Given parenterally.
Study NCT02563938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04077580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methenamine Hippurate 1000 MG
Description: Methenamine and placebo is taken 1 tablet morning and evening for 180 days
Study NCT04077580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methenamine Hippurate 1000 MG
Description: Methenamine and placebo is taken 1 tablet morning and evening for 180 days
Study NCT02472704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten challenge
Description: gluten (20 g/day) (identical powder sachets than placebo, mixed with meals) rechallenge while on a gluten-free diet
Study NCT02472704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo challenge
Description: placebo (maltrodextrin) (identical powder sachets than gluten, mixed with meals) rechallenge while on a gluten-free diet
Study NCT00296140 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: self management of PSD symptoms
Study NCT00296140 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: screening and treatment of PSD
Study NCT03491111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training for EMT+IMT
Description: 2 times per day and 5 day per week, 6 weeks, training with breathing trainer.
Study NCT03491111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Rehabilitation
Description: Regular Rehabilitation: 2-3 times a week, 6 weeks.
Study NCT03491111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Rehabilitation
Description: Regular Rehabilitation: 2-3 times a week, 6 weeks.
Study NCT03481010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PAO with hip arthroscopy
Description: Participants who are randomized to the Scope-PAO group will receive central compartment hip arthroscopy in addition to the PAO.
Study NCT03481010 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PAO without hip arthroscopy
Description: Participants who are randomized to the PAO-only group will receive a Bernese Periacetabular Osteotomy (PAO) for treatment of hip dysplasia.
Study NCT03491111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training for EMT
Description: 5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
Study NCT03041896 — intervention group
Intervention type: DEVICE
Intervention: coflex® Interlaminar Technology
Description: Interlaminer Technology
Study NCT04342455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: double-low scanning
Description: a CT angiography protocol with low radiation and contrast agent exposure
Study NCT01380600 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Description: Intravenous Dose Range: 1x10\^6 pfu/kg, 1x10\^7 pfu/kg, 3x10\^7 pfu/kg Up to 4 intravenous infusions administered over 60 minutes every 2 weeks.
Study NCT04038138 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Validation of new COA for FSHD patients
Description: Monitoring of commonly used and news COA in patients with facioscapulohumeral muscular dystrophy
Study NCT02393352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling Therapy
Description: The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
Study NCT02393352 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation Therapy
Study NCT04201184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Newly created cultural components, adapted Family Spirit lessons, adapted CETA modules
Description: Caregivers will receive 12 lessons, weekly, over a period of 12 weeks. Full curriculum contains: 4 lessons on cultural connection and traditions, 4 lessons on parenting adapted from Family Spirit intervention, and 4 lessons on stress and trauma adapted from CETA. modules
Study NCT04201184 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active nutrition control
Description: The active control condition will receive nutrition information, weekly food boxes and recipes. Recipes will be developed based on seasonal foods and a shopping list for making future meals will be included.
Study NCT02408263 — intervention group
Intervention type: PROCEDURE
Intervention: Total Hip Replacement (THR) and Total Knee Replacement (TKR)
Description: Total Hip Replacement is a surgical procedure where the cartilage and bone of the hip joint is replaced with artificial materials. Total Knee Replacement involves replacement of all three compartments of the knee the medial, the lateral and patellofemoral compartment.
Study NCT03679871 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire validation
Description: Participants will fill in the questionnaire Spiritual Resources and Distressplus additional questionnaires required for validation purposes. Three weeks later, a sub-sample will fill in the questionnaire one more time for consistency testing (test-retest)
Study NCT04327245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention ingest a 5000 mg of D-tagatose
Description: Woman with resistance insulin who ingest a 5000 mg of D-tagatose. D-tagatose is a sweetener of natural origin, low in calories (1.5 kcal / g) and with a sweetness power of 0.9.~About 20 to 25% of the ingested D-tagatose is absorbed and metabolized in the liver, the rest is fermented by the microbiota producing short chain fatty acids.
Study NCT04327245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention ingest a 15,3 mg of stevia
Description: Woman with resistance insulin who ingest a 15,3 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)
Study NCT00745004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Over-encapsulated 4mg ondansetron tablets. Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days. For 5 weeks.
Study NCT00745004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule matching over-encapsulated experimental drug. 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days. For 5 weeks.
Study NCT02651038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Measurement of PK
Study NCT03647098 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy.
Description: pemetrexed, 500mg/m2, ivgtt every 21 day.
Study NCT00222066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetal ovarian cyst aspiration
Description: Fetal ovarian cyst aspiration performed under ultrasound guidance and maternal local anesthesia
Study NCT02950168 — intervention group
Intervention type: PROCEDURE
Intervention: Edoxaban
Description: Edoxaban according to Summary of Product Characteristic (SMPC)
Study NCT00520273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cobas s 201 TaqScreen MPX Test
Description: Donors testing reactive for one or more of the viral markers will be advised to seek further advice/treatment from their physician.
Study NCT02206230 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy
Study NCT02206230 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard radiation therapy
Study NCT02023515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional brain training
Description: Stress management based program
Study NCT04481217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-questionnaires battery
Description: * Childhood trauma questionnaire (Bernstein, Ahluvalia, Pogge, \& Handelsman, 1997; Bernstein et al., 2003)~* The Young schema questionnaire short form (SQ-SF ; Cottraux \& Black, 2006; Young, 1998).~* Dissociative experiences scale (Laroi et al., 2013).~* Launay-Slade hallucination scale (Bentall \& Slade, 1985; Launay \& Slade, 1981)~* Cardiff Anomalous Perceptions Scale (Bell et al., 2006)
Study NCT04481217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Socio-demographic screening
Description: age; gender; education; highest diploma; job; marital status; living place
Study NCT02023515 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral weight loss
Description: Standard behavioral weight loss
Study NCT03773887 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: collection of liver biopsies collection of blood samples
Description: blood and ascites samples; extraction of explants, hepatic resection parts; hepatic parenchyma on liver biopsies
Study NCT00788892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Study NCT00788892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Study NCT00788892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Study NCT03774277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Packed Promise for a Healthy Heart
Description: Voucher for fresh vegetables and fruits (referred to as a fresh check); Home delivered food boxes that contain Dietary Approaches to Stop Hypertension (DASH)-approved ingredients for preparing low-salt, and traditional healthy Chickasaw meals; Heart-healthy recipes (available at getfreshcooking.com) that are tailored to traditional Chickasaw diet and culture; Educational materials; Personalized invitation to attend local cooking demonstrations; Assistance to link the Fitbit and AYA app
Study NCT02519127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycaemic load diet
Description: Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a low glycemic load diet for 6 weeks.
Study NCT02519127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western diet
Description: Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a 'Western' diet for 6 weeks.
Study NCT02445963 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shigella flexneri 2a InvaplexAR
Description: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
Study NCT03876626 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PositiveLinks RX Mobile App
Description: A mobile app designed with tools to facilitate patient self-monitoring, patient-provider communication, medication refills, and social support.
Study NCT03876626 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PositiveLinks RX Portal
Description: An online portal that interacts with the mobile app to enable users to engage with participants though messaging and medication refill tracking.
Study NCT00426101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg/m2 daily wk 1-2 5 mg/m2 daily wk 3-4 2.5 mg/m2 daily wk 5-6 1.25 mg/m2 daily wk 7 Steroids tapered wk 8~If continuation:~Pulses every 2nd wk, 10 mg/m2 for 3 days
Study NCT00426101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m2 iv twice/wk (wk 1-2) 150 mg/m2 iv once/wk (wk 3-8)~If continuation:~150 mg/m2 iv, every 2nd wk
Study NCT00426101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Description: WK 1-8:~- Aim at around 200 microgram/L (trough value). Start: 6 mg/kg daily (divided in 2 daily doses) wk 1, if kidney function is normal.~If continuation:~- Aim for around 200 microgram/L. Monitor GFR.
Study NCT02209974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Administration of inhaled corticosteroids (fluticasone, 0.5 mg) each 12 hours to 8 of the 16 COPD patients versus placebo.
Study NCT02209974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Study NCT02643732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate (overencapsulated)
Description: 10mg (1 capsule) methylphenidate (standard release) twice daily, increased to 20mg (2 capsules) twice daily after 2 weeks. The drug can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
Study NCT03872089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infrared Thermography
Description: Measurements of the temperature of the plantar arch by thermal imaging (Infrared Thermography)
Study NCT02482103 — intervention group
Intervention type: PROCEDURE
Intervention: Renal denervation
Description: Catheter based renal nerve ablation
Study NCT03098537 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: enteral nutrition + proton pump inhibitor
Description: Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive enteral nutrition and proton pump inhibitor
Study NCT03098537 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enteral nutrition only
Description: Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive only enteral nutrition.
Study NCT00537381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 as intravenous infusion every 3 weeks.
Study NCT00537381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 as intravenous infusion every 3 weeks.
Study NCT00537381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg orally twice daily.
Study NCT00537381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 5 mg orally twice daily.
Study NCT00537381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intetumumab
Description: Intetumumab 10 mg/kg as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
Study NCT02643732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Over-encapsulated tablet)
Description: Identical capsules (over-encapsulated placebo tablets), administered initially one capsule twice daily, increased to 2 capsules after 2 weeks. As with the methylphenidate arm, the dose can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
Study NCT04325230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arterial Spin Labeling sequence
Description: ASL sequence added to the usual care brain MRI